CAR T-Cell Therapy

Early steroid intervention has the potential to reduce the severity of adverse events associated with axicabtagene ciloleucel in patients with refractory large B-cell lymphoma, according to an analysis of the phase I/II ZUMA-1 trial.

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

Jeremy S. Abramson, MD, discusses the results of the multicenter phase I TRANSCEND NHL 001 study evaluating the safety and efficacy of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

The FDA has granted a priority review designation to a biologics license application for the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.

Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Ankit Kansagra, MD, discusses the expanding role of CAR T-cell therapy in lymphoma and multiple myeloma.

Praveen Ramakrishnan, MD, spotlights some of the exciting data recently presented across the spectrum of non-Hodgkin lymphoma treatment.

Ankit Kansagra, MD, discusses the evolving use of CAR T-cell therapy in multiple myeloma and lymphoma.

CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors.

Minimal residual disease has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia.

Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.